Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXT107 (gersizangitide) in neovascular AMD
NCT05859776Phase 2Active, not recruiting
- Sponsor
- AsclepiX Therapeutics
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of gersizangitide in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by AsclepiX Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 40 weeks. Started Dec 2023; status: active, not recruiting.
02
Drugs
gersizangitide
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05859776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859776.